http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109939127-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79374ae0c28a7f4fb3dc1a2f97a73657 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate | 2019-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcf82d35f45139ef625fda72d5f3e44a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ebf87f7032abf12b6d63e35a0560c3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8426fab50fa6f367ede6e70c51f76ff |
| publicationDate | 2019-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109939127-A |
| titleOfInvention | Application of NK cell and pharmaceutical composition comprising the NK cell and application thereof |
| abstract | The invention discloses an application of an NK cell, a pharmaceutical composition comprising the NK cell, and the application thereof. The application is that PD-1 or PD-L1 changes from negative to positive or from low expression in the preparation of tumor microenvironment by NK cells. Application to highly expressed drugs; the anti-tumor pharmaceutical composition includes the above-mentioned NK cells in an effective therapeutic amount, and a target drug that specifically binds to PD-1 or PD-L1, and the target drug is combined with PD-1 or PD-L1. -1 or PD-L1 specifically binds to block the interaction between PD-1 and PD-L1. The beneficial effects of the present invention are: by adding NK cells to cancer (tumor) cells with negative or low expression of PD-1 or PD-L1, it is unexpectedly found that PD-1 or PD-L1 in tumor cells can be converted from negative to negative positive, or from low expression to high expression, thereby effectively preventing the occurrence of immune escape in tumor cells and improving the therapeutic effect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115873133-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115873133-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115491355-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115491355-B |
| priorityDate | 2018-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 318.